Shots:

• The first patient has been dosed in a P-III program that consists of P-III ADORING 1/2 and long-term extension ADORING 3 study evaluates the safety and efficacy of tapinarof (1% dosed- qd) vs vehicle-controlled cream in patients aged ≥2yrs. with AD
• The 1EPs of ADORING 1/2 studies will be the proportion of patients achieving a vIGA-AD of 0 or 1 with at least a 2-grade improvement from baseline @8wks. Additionally- the ADORING 3 study will consist of up to 48wks. with a 7-day safety follow-up period
• Tapinarof is a steroid-free- cosmetically elegant topical cream & a therapeutic aryl hydrocarbon receptor modulating agent for the treatment of PsO and AD

| Ref: Businesswire | Image: PharmaLive